UAE Stent Market Industry Size, Share, Trends, Opportunity, and Forecast, Segmented by Product Type (Vascular Stents {Coronary Stents, Peripheral Stents, Naurovascular Stents}, Non-Vascular Stents {Gastrointestinal Stents, Urological Stents, Pulmonary (Airway) Stents}), By Material Type (Metal, Polymer), By Type (Balloon Expandable, Self-Expandable), By End User (Hospitals & Clinics, Ambulatory Care Centers, Others), by region, and Competition 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 60.71 Million
CAGR (2026-2031)	4.14%
Fastest Growing Segment	Hospitals & Clinics
Largest Market	Abu Dhabi
Market Size (2031)	USD 77.44 Million

Market Overview

The UAE Stent Market will grow from USD 60.71 Million in 2025 to USD 77.44 Million by 2031 at a 4.14% CAGR. A stent is a small, expandable mesh tube, typically composed of metal or plastic, designed to be inserted into a narrowed or weakened artery to restore blood flow and prevent vessel collapse. The primary drivers supporting the UAE Stent Market include the rising prevalence of cardiovascular diseases, exacerbated by lifestyle factors such as obesity and diabetes, alongside substantial government investments in domestic healthcare infrastructure to reduce reliance on outbound medical tourism. According to Mecomed, in 2024, the UAE medical technology market was projected to reach US$ 3.02 billion, reflecting the region's accelerated adoption of advanced interventional solutions.

However, the market faces a significant challenge regarding stringent regulatory pricing controls and cost-containment measures enforced by local health authorities. These unified procurement policies aim to standardize costs across the Emirates but often exert downward pressure on device prices, thereby compressing profit margins for international manufacturers. Consequently, companies must navigate a complex reimbursement landscape and intense competitive pricing strategies to sustain their market positioning within the region.

Key Market Drivers

The rising prevalence of lifestyle-induced cardiovascular diseases serves as the foremost catalyst propelling the UAE Stent Market. Rapid urbanization has led to sedentary lifestyles and dietary shifts, resulting in a surge of obesity and diabetes cases that significantly elevate the risk of coronary artery disease. This demographic shift has necessitated a higher volume of interventional procedures, directly increasing the demand for angioplasty and stenting solutions to manage complex heart conditions. Demonstrating this trend, according to Burjeel Holdings, March 2025, in the 'FY 2024 Financial Results', the group reported an 11% year-on-year revenue growth in its cardiology segment, driven by a surge in patient footfall and specialized procedures. This uptick in cardiac care reflects the acute market need for effective therapeutic devices to mitigate the growing burden of heart ailments among the local population.

Simultaneously, the expansion of the UAE as a regional medical tourism hub is reshaping the market landscape, attracting international patients seeking high-quality cardiovascular treatments. Authorities are actively funding the modernization of healthcare infrastructure to support this influx, thereby boosting the consumption of premium stent technologies. According to the UAE Government Portal, May 2025, in the 'Healthcare budget' update, the federal government allocated AED 5.745 billion to healthcare and community prevention services for the fiscal year 2025, ensuring state-of-the-art facilities. This investment is yielding tangible results in patient acquisition; according to Cleveland Clinic Abu Dhabi, February 2025, in the 'Cleveland Clinic Abu Dhabi reports 35% growth in international patient volume for 2024' press release, the facility recorded a 35% increase in international patient encounters in 2024, underscoring the nation's successful positioning as a preferred destination for advanced cardiac interventions.

Download Free Sample Report

Key Market Challenges

The stringent regulatory pricing controls and cost-containment measures enforced by local health authorities represent a formidable barrier to the growth of the UAE Stent Market. These unified procurement policies, exemplified by centralized purchasing bodies, aim to standardize healthcare costs across the Emirates but simultaneously exert significant downward pressure on device prices. International manufacturers are consequently compelled to navigate a highly price-sensitive environment where profit margins are compressed, and the financial viability of introducing premium, high-cost stent technologies is challenged. The focus on reducing expenditure often favors cost-efficiency over advanced innovation, forcing companies to engage in aggressive competitive pricing strategies to maintain their market positioning.

This restrictive financial landscape is largely a response to the region's escalating healthcare burden, which necessitates strict budget management by government payers. According to the U.S.-U.A.E. Business Council, in 2025, approximately 17% of the UAE population aged 20 to 79 was reported to suffer from type 2 diabetes, a primary risk factor driving the high volume of cardiovascular interventions. While this prevalence ensures a steady demand for stent procedures, the corresponding need to control the aggregate cost of treating such a large patient base reinforces the regulator's resolve to cap unit prices, thereby hampering revenue growth for device suppliers despite the increasing procedural volume.

Key Market Trends

The incorporation of Artificial Intelligence (AI) in interventional planning is revolutionizing the UAE Stent Market by enhancing diagnostic accuracy and optimizing procedural outcomes. Hospitals are increasingly deploying AI-driven algorithms to analyze complex physiological data and angiographic imagery, enabling cardiologists to identify lesion severity and select precise stent dimensions before catheterization. This predictive capability reduces the risk of complications such as stent thrombosis and restenosis, fostering a shift toward personalized preventive cardiology. Demonstrating this technological leap, according to Gulf News, September 2025, in the 'Medcare unveils AI technology to spot heart disease before it even begins' article, Medcare Hospitals introduced an AI-powered diagnostic tool capable of predicting the development of coronary artery disease with 95% accuracy, significantly aiding clinicians in early intervention planning.

Simultaneously, the utilization of intravascular imaging for precision deployment has emerged as a critical trend, driven by the need for superior visualization during complex structural and coronary interventions. Advanced modalities such as Intracardiac Echocardiography (ICE), Intravascular Ultrasound (IVUS), and Optical Coherence Tomography (OCT) are becoming standard in high-volume catheterization labs to guide the accurate placement of stents and scaffolds, ensuring optimal apposition and vessel patency. This adoption is particularly evident in high-risk procedures where precision is paramount to patient safety and long-term device performance. For instance, according to Gulf News, September 2025, in the 'How Cleveland Clinic Abu Dhabi is redefining heart care in the UAE' report, the facility successfully performed more than 650 Transcatheter Aortic Valve Replacement (TAVR) procedures utilizing continuous monitoring and intracardiac echo guidance to ensure exact device deployment.

Segmental Insights

The Hospitals and Clinics segment constitutes the fastest growing category in the UAE stent market due to the rapid expansion of specialized healthcare infrastructure. This growth is primarily driven by initiatives from the Ministry of Health and Prevention to enhance cardiac care capabilities in response to the rising prevalence of cardiovascular diseases. Furthermore, the enforcement of mandatory health insurance coverage across the Emirates has significantly improved patient access to essential interventional procedures. Consequently, medical facilities are experiencing higher procedural volumes, leading to a sustained increase in the demand for stents within the hospital sector.

Regional Insights

Abu Dhabi maintains the leading position in the UAE stent market due to robust healthcare infrastructure and strategic initiatives led by the Department of Health – Abu Dhabi. The region benefits from a high concentration of specialized cardiac centers and significant government investment in interventional cardiology services. This institutional support directly addresses the rising prevalence of cardiovascular diseases, fostering a consistent demand for stent implantation procedures. Consequently, favorable regulatory policies and focused resource allocation establish the emirate as the primary contributor to regional market revenue.

Recent Developments

• In December 2024, B. Braun’s latest bioresorbable technology, the Fantom Encore stent, was successfully utilized in a breakthrough procedure at Al Qassimi Hospital. This event marked the reintroduction of this specific class of biodegradable stents in the facility, utilizing a device composed of a polymer that incorporates the amino acid tyrosine to facilitate safe degradation. The stent is engineered to provide structural support to the vessel before dissolving over time, preserving the artery's natural movement and function. This development underscored the continued innovation within the UAE stent market, focusing on devices that improve long-term vessel health by eliminating permanent metallic residues.
• In September 2024, Abbott introduced its latest interventional technology in the UAE with the first successful implantation of the Esprit BTK Everolimus Eluting Resorbable Scaffold System at Al Qassimi Hospital. This device is the first dissolvable stent of its kind available in the country specifically for treating chronic limb-threatening ischemia in arteries below the knee. The system allows the vessel to heal and stay open while delivering medication, eventually dissolving completely. This product launch addressed a critical need in the market for treating peripheral artery disease and preventing amputations, further diversifying the range of stent technologies available to patients in the Emirates.
• In May 2024, Boston Scientific expanded its operational footprint in the United Arab Emirates by inaugurating a new distribution center in Dubai. Located in Dubai South, this facility was established to enhance the supply chain capabilities for the company’s medical technologies, including its interventional cardiology portfolio, across the Middle East, Africa, and Asia. The center, which is designed to handle a significant volume of medical units, aims to reduce logistics lead times and ensure faster delivery of critical devices such as stents to healthcare providers. This strategic development highlights the company's commitment to strengthening its infrastructure and supporting the growing demand for advanced medical solutions in the region.
• In May 2024, Biotronik’s advanced vascular intervention technology was introduced to the region when Al Qassimi Hospital in Sharjah successfully implanted the Freesolve resorbable magnesium scaffold. This procedure marked the first use of this third-generation magnesium-based stent in the Middle East. The Freesolve scaffold is designed to provide support to the vessel during the healing process and then gradually dissolve, which helps in restoring the natural function of the artery. This launch represented a significant technological advancement in the UAE stent market, offering a new bioresorbable option for treating coronary artery disease that avoids the permanent presence of a metal implant.

Key Market Players

• Medtronic Meta FZ-LLC
• Boston Scientific Corporation UAE
• Becton Dickinson, and Company
• CONMED Corporation UAE
• Stryker ESCS BV
• Abbott Laboratories S. A
• B. Braun Medical Inc
• Terumo Middle East FZE
• Cook Medical UAE
• Vasmed UAE

By Material Type	By Type	By End User	By Region
Metal Polymer	Balloon Expandable Self-Expandable	Hospitals & Clinics Ambulatory Care Centers Others	Dubai Abu Dhabi Sharjah Rest of UAE

Report Scope:

In this report, the UAE Stent Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• UAE Stent Market, By Material Type:

• Metal
• Polymer

• UAE Stent Market, By Type:

• Balloon Expandable
• Self-Expandable

• UAE Stent Market, By End User:

• Hospitals & Clinics
• Ambulatory Care Centers
• Others

• UAE Stent Market, By Region:

• Dubai
• Abu Dhabi
• Sharjah
• Rest of UAE